BioNTech reported second quarter revenue of €105.6 million, a sharp decrease from €260.8 million in the prior-year period, primarily due to declining COVID-19 vaccine sales. The company posted a net loss of €820.8 million, or a loss of €3.24 per share, which widened considerably from a net loss of €386.6 million, or €1.60 per share, in the second quarter of 2025.
Key Highlights
- Revenue Decline: Total Q2 revenues decreased by 59.5% year-over-year, with COVID-19 vaccine revenues falling to €51.9 million from €153.3 million in the same quarter last year.
- Widening Losses: The net loss for the quarter more than doubled to €820.8 million compared to the prior-year period, reflecting lower revenue and increased operating expenses.
- Increased R&D Investment: Research and development expenses rose 8% year-over-year to €551.0 million, driven by higher spending on immuno-oncology and ADC programs, as well as impairments on some early-stage product candidates.
- Sales & Marketing Ramp-Up: Sales and marketing expenses more than doubled to €40.1 million from €19.7 million year-over-year as the company conducts pre-launch activities for its late-stage pipeline.